Bristol Myers Squibb (BMY)
(Real Time Quote from BATS)
$55.30 USD
+0.98 (1.80%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $55.46 +0.16 (0.29%) 4:16 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.30 USD
+0.98 (1.80%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $55.46 +0.16 (0.29%) 4:16 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
by Zacks Equity Research
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo versus docetaxel was stopped earlier than expected as it met the primary endpoint.
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
by Zacks Equity Research
Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
by Zacks Equity Research
The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.
Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes
by Arpita Dutt
Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.
3 Companies Competing to Gain Lead in Ovarian Cancer Market
by Zacks Equity Research
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
by Arpita Dutt
Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.
J&J Seeks Darzalex's Label Expansion in First-Line Setting
by Zacks Equity Research
Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.
LabCorp Reports New Use of Agilent's Cancer Diagnostic Test
by Zacks Equity Research
The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
by Arpita Dutt
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
by Zacks Equity Research
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat
by Zacks Equity Research
Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.
Pharma ETFs Down Post Q3 Earnings
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
by Zacks Equity Research
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.
Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
by Arpita Dutt
It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright